Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 86,400 shares, a decline of 15.4% from the April 30th total of 102,100 shares. Based on an average trading volume of 151,700 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.6% of the shares of the company are short sold.

Hedge Funds Weigh In On Aethlon Medical

Several large investors have recently made changes to their positions in AEMD. Virtu Financial LLC purchased a new position in Aethlon Medical in the fourth quarter valued at $81,000. Boothbay Fund Management LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter valued at about $186,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at about $31,000. Allegiance Financial Group Advisory Services LLC acquired a new position in Aethlon Medical in the 4th quarter worth about $26,000. Finally, Armistice Capital LLC purchased a new position in Aethlon Medical during the first quarter worth approximately $511,000. 1.99% of the stock is currently owned by institutional investors and hedge funds.

Aethlon Medical Price Performance

NASDAQ AEMD opened at $0.36 on Tuesday. The company has a fifty day moving average of $0.37 and a 200 day moving average of $0.49. The company has a market capitalization of $5.77 million, a PE ratio of -0.23 and a beta of 1.93. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.06.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Monday, March 10th. Wall Street Zen initiated coverage on Aethlon Medical in a research report on Thursday, May 15th. They issued a “sell” rating on the stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.